Skip to main content
eScholarship
Open Access Publications from the University of California

Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years

  • Author(s): Kwan, A
  • Church, JA
  • Cowan, MJ
  • Agarwal, R
  • Kapoor, N
  • Kohn, DB
  • Lewis, DB
  • McGhee, SA
  • Moore, TB
  • Stiehm, ER
  • Porteus, M
  • Aznar, CP
  • Currier, R
  • Lorey, F
  • Puck, JM
  • et al.

Published Web Location

http://www.sciencedirect.com/science/article/pii/S0091674913006714
No data is associated with this publication.
Abstract

Background: Assay of T-cell receptor excision circles (TRECs) in dried blood spots obtained at birth permits population-based newborn screening (NBS) for severe combined immunodeficiency (SCID). Objective: We sought to report the first 2 years of TREC NBS in California. Methods: Since August 2010, California has conducted SCID NBS. A high-throughput TREC quantitative PCR assay with DNA isolated from routine dried blood spots was developed. Samples with initial low TREC numbers had repeat DNA isolation with quantitative PCR for TRECs and a genomic control, and immunophenotyping was performed within the screening program for infants with incomplete or abnormal results. Outcomes were tracked. Results: Of 993,724 infants screened, 50 (1/19,900 [0.005%]) had significant T-cell lymphopenia. Fifteen (1/66,250) required hematopoietic cell or thymus transplantation or gene therapy; these infants had typical SCID (n = 11), leaky SCID or Omenn syndrome (n = 3), or complete DiGeorge syndrome (n = 1). Survival to date in this group is 93%. Other T-cell lymphopenic infants had variant SCID or combined immunodeficiency (n = 6), genetic syndromes associated with T-cell impairment (n = 12), secondary T-cell lymphopenia (n = 9), or preterm birth (n = 8). All T-cell lymphopenic infants avoided live vaccines and received appropriate interventions to prevent infections. TREC test specificity was excellent: only 0.08% of infants required a second test, and 0.016% required lymphocyte phenotyping by using flow cytometry. Conclusions: TREC NBS in California has achieved early diagnosis of SCID and other conditions with T-cell lymphopenia, facilitating management and optimizing outcomes. Furthermore, NBS has revealed the incidence, causes, and follow-up of T-cell lymphopenia in a large diverse population. © 2013 American Academy of Allergy, Asthma &Immunology.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Item not freely available? Link broken?
Report a problem accessing this item